key: cord-0753135-fobqb19q
authors: Gupta, Tejpal; Thakkar, Prafulla; Kalra, Babusha; Kannan, Sadhana
title: Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta‐analysis
date: 2021-07-10
journal: Rev Med Virol
DOI: 10.1002/rmv.2276
sha: 14a876c5310f03dc11f42eb474a65cb469a515c7
doc_id: 753135
cord_uid: fobqb19q

Coronavirus disease 2019 (COVID‐19) caused by the novel severe acute respiratory syndrome coronavirus 2 continues to grow and spread throughout the world since being declared a pandemic. Despite extensive scientific research globally including repurposing of several existing drugs, there is no effective or proven therapy for this enigmatic disease which is still largely managed empirically This systematic review evaluated the role of hydroxychloroquine (HCQ) in the treatment of COVID‐19 infection and was conducted using Cochrane methodology for systematic reviews of interventional studies including risk of bias assessment and grading of the quality of evidence. Only prospective clinical trials randomly assigning COVID‐19 patients to HCQ plus standard of care therapy (test arm) versus placebo/standard of care (control arm) were included. Data were pooled using the random‐effects model and expressed as risk ratio (RR) with 95% confidence interval (CI). A total of 10,492 patients from 19 randomised controlled trials were included. The use of HCQ was not associated with higher rates of clinical improvement (RR = 1.00, 95% CI: 0.96–1.03, p = 0.79) or reduction in all‐cause mortality by Day14 (RR = 1.07, 95% CI: 0.97–1.19, p = 0.19) or Day28 (RR = 1.08, 95% CI: 0.99–1.19, p = 0.09) compared to placebo/standard of care. There was no significant difference in serious adverse events between the two arms (RR = 1.01, 95% CI: 0.85–1.19, p = 0.95). There is low‐to‐moderate certainty evidence that HCQ therapy is generally safe but does not reduce mortality or enhance recovery in patients with COVID‐19 infection.

resultant heterogeneous clinical spectrum. 3, 4 Despite extensive scientific research globally including repurposing of several existing drugs, there is no effective or proven therapy for this enigmatic disease which is still largely managed empirically. 4, 5 A plethora of medical and pharmacological therapies including antivirals, antibiotics, anti-malarials, anti-parasitic agents, non-steroidal anti-inflammatory drugs, corticosteroids and immunomodulators are currently being investigated in over a thousand randomised controlled trials (RCTs) across the world with an aim to generate high-quality evidence to inform and guide clinical practice during the ongoing pandemic. [6] [7] [8] [9] [10] [11] Various anti-viral drug groups such as fusion inhibitors (umifenovir), protease inhibitors (lopinavir/ritonavir), neuraminidase inhibitors (oseltamivir) and nucleotide reverse transcriptase inhibitors (remdesivir and favipiravir) have been tested in multiple prospective studies since the outbreak of the pandemic. 12, 13 Only about 9 months ago, remdesivir became the first drug to receive United States Food and Drug Administration (US-FDA) approval for treatment of hospitalised COVID-19 patients. 14 Hydroxychloroquine (HCQ), a less toxic derivative of chloroquine (CQ) is a widely used anti-parasitic agent for malaria and immunomodulatory drug for rheumatologic diseases. In the lab, HCQ has demonstrated impressive activity against COVID-19 by blocking the entry of SARS-CoV-2 into cells by inhibiting glycosylation of cell-surface receptors, interfering with proteolytic processing and increasing endosomal pH to limit endosome-mediated viral entry and late-stage viral replication. 15, 16 In addition, HCQ reduces the production of several pro-inflammatory cytokines potentially involved in the development and progression to acute respiratory distress syndrome in patients with COVID-19 infection.

Based on promising in vitro activity and favourable clinical experience in observational studies 17, 18 during early phase of the pandemic, HCQ received emergency use authorisation (EUA) from US-FDA in March 2020, which was revoked later due to concerns regarding cardiac toxicity. 19, 20 Over a year and half into the pandemic, several RCTs have investigated and reported on the safety and efficacy of HCQ as a prophylactic and therapeutic agent in COVID-19 infection. Multiple systematic reviews and meta-analyses of HCQ treatment in COVID-19 have also been reported with conflicting and contradictory results. A meta-review 21 of systematic reviews and updated meta-analysis concluded that treatment with HCQ and CQ with or without azithromycin did not reduce mortality in COVID-19 infection but was associated with a higher risk of adverse events.

However, despite the lack of clear evidence of efficacy and presence of valid concerns regarding safety, HCQ continues to be used widely in the management of COVID-19 infection.

The aim of this rapid, updated, structured systematic review and direct comparison meta-analysis was to evaluate the safety and efficacy of HCQ in the treatment of COVID-19 for generating highquality evidence to inform and guide therapeutic decision-making.

This systematic review was conducted using Cochrane methodology for systematic reviews of interventional studies 22 and reported in accordance with the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 23 Data analysis included risk of bias assessment using Cochrane Risk of Bias tool 24 

The flow diagram of study selection and inclusion in the metaanalysis as per the PRISMA guidelines is depicted in Figure 1 . 

There was modest methodologic heterogeneity across the 19 included studies prompting the use of random-effects model for statistical pooling of data. (Table 1 ).

The outbreak of COVID-19 pandemic prompted the scientific and medical community not only to develop new and/or novel medical therapies but also to explore the possibility of repurposing existing drugs with promising anti-viral activity against SARS-CoV-2. 2,5 A widely used anti-malarial and anti-rheumatic drug CQ and its less retracted due to concerns regarding authenticity and integrity of data. 46 The FDA authorisation for HCQ was later revoked in June 2020 based on emerging data on the lack of efficacy and valid concerns regarding cardiac safety. 19, 20 Early evidence for the efficacy of HCQ in COVID-19 was initially The conflicting comparative evidence between big data and the real world 56 on the effectiveness of HCQ in COVID-19 has led to divided opinion within the medical community. Big data observational studies are associated with conflicts of interest, lack details on HCQ dosage and duration, and have shown the absence of efficacy. On the other hand, real-world data from clinical studies have reported favourable clinical and virological outcomes with HCQ including trend towards reduction in mortality. 56 A comparison of the mortality estimates from COVID-19 between developing countries (manly from Asia and Far East) that adopted CQ/HCQ early versus those that expressed concerns regarding its usage (developed countries mainly in Europe and America) shows a striking inverse relationship between widespread CQ/HCQ usage and deaths per million population, which warrants more in-depth analysis. 57 The current systematic review and meta-analysis (including both RE-COVERY and Solidarity) thus provides the largest (over 10,000 randomised patients) and most updated contemporary evidence regarding the safety and efficacy of HCQ in the treatment of COVID-19 infection. The addition of HCQ to current standard of care therapy is not associated with statistically significant or clinically meaningful benefit (reduction in mortality or improvements in clinical recovery and/or virological clearance). Reassuringly, HCQ is neither associated with serious harm compared to placebo/standard of care therapy allaying fears regarding its safety.

An analysis of the WHO-ICTRP database 58 in April 2020 had identified a total of 51 registered RCTs evaluating CQ or HCQ, either T A B L E 1 Summary of findings for the safety and efficacy of hydroxychloroquine compared to controls (placebo/standard of care therapy) in COVID-19 infection including the quality of evidence with grade of recommendation 

Despite being the largest data set derived only from RCTs and pooled using modern meta-analytic methods, certain caveats and limitations remain. Large majority of studies including the two largest trials (RECOVERY and Solidarity) were open-label without any placebocontrols with significant potential for performance and detection bias. The standard of care therapy (control arm) as well as dose and duration of HCQ therapy (test arm) was variable across studies further confounding the analyses and inferences. Finally, unpublished data from completed or prematurely terminated trials were not available for pooling in the meta-analysis. However, given the number of randomised patients included in the analysis, it is highly unlikely that any further updated pooled analysis would substantially enhance the certainty of evidence or improve the strength of recommendation.

There is low to moderate certainty evidence that HCQ therapy is generally safe but does not reduce mortality or enhance clinical/ virological recovery compared to placebo/standard of care therapy in patients with COVID-19 infection.

No financial support was involved in the study.

None of the authors have any conflicts of interest to declare.

Not applicable.

Tejpal Gupta: Conceptualization, Methodology, Analysis, and Writing 

https://orcid.org/0000-0001-8256-9206

Covid-19: WHO declares pandemic because of 'alarming levels' of spread, severity, and inaction

A coordinated global research roadmap: 2019 Novel coronavirus

Clinical, laboratory, and imaging features of COVID-19: a systematic review and meta-analysis

Coronavirus disease 2019 (COVID-19): a literature review

Emergence of novel coronavirus and progress toward treatment and vaccine

Current pharmacological modalities for management of novel coronavirus 2019 (COVID-19) and the rationale for their utilization: a review

Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection

Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection

Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies

Systematic review and metaanalysis of randomized controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practice and implications for research

Antivirals for COVID-19: a critical review

Remdesivir and its antiviral activity against COVID-19: a systematic review

FDA's approval of Veklury (remdesivir) for the treatment of COVID-19 -the Science of Safety and Effectiveness

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label, nonrandomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine

A meta-review of systematic reviews and updated meta-analysis on the efficacy of chloroquine and hydroxychloroquine in treating COVID19 infection

Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap

Hydroxychloroquine in the treatment of COVID-19: a multicentre randomized controlled study

An open-label randomized controlled trial of the effect of lopinovir/ritonavir, lopinavir/ ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

Hydroxychloroquine vs azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized active comparator trial

Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19

A multicentre, randomized, openlabel, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv

Hydroxychloroquine in mild-tomoderate COVID-19: a placebo-controlled double blind trial

Effect of hydroxychloroquine in hospitalized patients with COVID-19

Clearing the fog: is hydroxychloroquine effective in reducing coronavirus disease-2019 progression? a randomized controlled trial

A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomizedcontrolled trial

Randomized doubleblinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19

Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results

Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial

Hydroxychloroquine in non-hospitalized adults with early COVID-19: a randomized trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomized controlled trial

Treating COVID-19 with hydroxychloroquine (TEACH): a multicentre, double-blind, randomized controlled trial in hospitalized patients

Retraction -hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis

Use of hydroxychloroquine in hospitalized COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study

Low-dose hydroxychloroquine therapy and mortality in hospitlaized patients with COVID-19: a nationwide observational study of 8075 participants

Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19

Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: a systematic review and meta-analysis

Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 pandemic

A pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation

Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2

Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic

Research response to COVID-19 needed better coordination and collaboration: a living mapping of registered trials

How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials

Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis